NasdaqGS - Nasdaq Real Time Price USD

Gilead Sciences, Inc. (GILD)

Compare
89.51 +0.69 (+0.78%)
At close: November 1 at 4:00 PM EDT
89.35 -0.16 (-0.18%)
After hours: November 1 at 7:56 PM EDT
Loading Chart for GILD
DELL
  • Previous Close 88.82
  • Open 88.31
  • Bid 89.50 x 300
  • Ask 89.54 x 500
  • Day's Range 88.19 - 89.57
  • 52 Week Range 62.07 - 89.74
  • Volume 5,291,053
  • Avg. Volume 6,114,746
  • Market Cap (intraday) 111.439B
  • Beta (5Y Monthly) 0.20
  • PE Ratio (TTM) 109.16
  • EPS (TTM) 0.82
  • Earnings Date Nov 6, 2024
  • Forward Dividend & Yield 3.08 (3.44%)
  • Ex-Dividend Date Sep 13, 2024
  • 1y Target Est 87.22

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

www.gilead.com

18,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GILD

View More

Performance Overview: GILD

Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GILD
14.05%
S&P 500
20.10%

1-Year Return

GILD
18.71%
S&P 500
36.60%

3-Year Return

GILD
56.22%
S&P 500
24.39%

5-Year Return

GILD
72.49%
S&P 500
88.60%

Compare To: GILD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GILD

View More

Valuation Measures

Annual
As of 11/1/2024
  • Market Cap

    111.44B

  • Enterprise Value

    132.02B

  • Trailing P/E

    109.16

  • Forward P/E

    12.22

  • PEG Ratio (5yr expected)

    0.52

  • Price/Sales (ttm)

    4.03

  • Price/Book (mrq)

    6.10

  • Enterprise Value/Revenue

    4.75

  • Enterprise Value/EBITDA

    25.05

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.79%

  • Return on Assets (ttm)

    11.55%

  • Return on Equity (ttm)

    5.26%

  • Revenue (ttm)

    27.8B

  • Net Income Avi to Common (ttm)

    1.05B

  • Diluted EPS (ttm)

    0.82

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.78B

  • Total Debt/Equity (mrq)

    128.32%

  • Levered Free Cash Flow (ttm)

    6.79B

Research Analysis: GILD

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 6.95B
Earnings 1.61B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

69.00 Low
87.22 Average
89.51 Current
123.00 High
 

Company Insights: GILD

Research Reports: GILD

View More
  • The Argus High-Yield Model Portfolio

    Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But in 2022, The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.

     
  • Raising target price to $85

    Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 18,000 employees.

    Rating
    Price Target
     
  • Stocks are up. Fed Chairman Powell injected some rocket fuel into the market

    Stocks are up. Fed Chairman Powell injected some rocket fuel into the market by saying, 'the time has come' to start cutting interest rates. The S&P 500 rose 1%, while the Dow gained 0.9% and the tech-heavy Nasdaq Composite was up 1.1%. The Russell 2000 added 3.3%. Both crude oil and gold were also up.

     
  • Gilead Earnings: Maintaining Our $97 Fair Value as Long-Term HIV Sales Potential Looks Undervalued

    Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

    Rating
    Price Target
     

People Also Watch